Allose-Based TLR Ligands for Stable Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Toll-like receptor (TLR) ligands, such as lipid A and its derivatives, suffer from limitations including toxicity, low potency, poor stability, and heterogeneity, which hinder their use in various therapeutic applications.
Innovation Solution
Development of novel TLR ligands with a stable allose-based scaffold, specifically compounds of formula (I) or their pharmaceutically acceptable salts, which exhibit improved stability in aqueous formulations and potential enhanced immunomodulatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipid A is used as a TLR4 agonist, then potent immune response is achieved, but extreme toxicity occurs including systemic inflammatory response syndrome
Solution Approach 1:
The patent extracts and modifies specific portions of the lipid A molecule. MPL (monophosphoryl lipid A) is produced by selective chemical modification that removes or alters the toxic phosphate groups while retaining the immunostimulatory acyl chain structure that activates TLR4 receptors.
Solution Approach 2:
The invention applies local quality modification by selectively modifying specific regions of the lipid A molecule. The acyl chain region is preserved to maintain TLR4 binding affinity, while the phosphate region is modified to reduce toxicity. This localized modification approach allows differential optimization of different molecular regions.
2Object-affected harmful factors
If MPL is used to reduce toxicity, then adjuvant activity is achieved, but heterogeneity and poor stability hinder therapeutic use
Solution Approach 1:
The patent employs parameter changes by systematically varying the chain lengths, saturation levels, and branching patterns of the acyl groups attached to the glycerol backbone. These parameter modifications allow optimization of both stability and immunogenicity. The invention also controls the stereochemistry and phosphorylation state to enhance formulation stability.
Solution Approach 2:
The invention creates composite lipid structures combining multiple acyl chains with specific properties. These composite molecules integrate saturated and unsaturated fatty acid chains, branched and straight-chain variants, and controlled phosphorylation patterns to achieve a balance between stability, solubility, and immunostimulatory activity.
3Reliability
If naturally sourced TLR4 ligands are used, then immune activation is achieved, but low potency and poor stability limit their application
Solution Approach 1:
The patent segments the complex lipid A structure into modular components that can be independently optimized. The molecule is divided into a glycerol backbone, multiple acyl chain positions, and phosphate groups. Each segment can be independently modified to control potency, specificity, and stability, allowing precise manufacturing of defined structures.
Solution Approach 2:
The invention systematically varies critical parameters including the length of acyl chains (C16, C18, C20, C22), their saturation state, branching patterns at specific carbon positions, and the degree of phosphorylation. These parameter changes enable fine-tuning of potency and purity for specific therapeutic indications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel TLR ligands demonstrate remarkable stability and efficacy in activating Toll-like receptors, eliciting immune responses, and potentially offering therapeutic benefits in treating or preventing diseases mediated by TLRs, such as infectious diseases, cancer, and autoimmune conditions.
Implementation Method 1
The TLR ligands of the invention have a novel allose-based scaffold with remarkable stability in aqueous formulation... demonstrate remarkable stability and efficacy in activating Toll-like receptors, eliciting immune responses
Data Source
AI summary
Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.